研究者業績

齋藤 心

サイトウ シン  (SHIN SAITO)

基本情報

所属
自治医科大学 医学部外科学講座 消化器一般移植外科学部門 学内准教授
学位
医学博士(2011年3月 自治医科大学)

研究者番号
60382909
ORCID ID
 https://orcid.org/0000-0002-2931-4260
J-GLOBAL ID
202001020402860887
researchmap会員ID
R000015064

主要な経歴

 1

学歴

 2

論文

 188
  • 金丸 理人, 大澤 英之, 高橋 和也, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 宮戸 秀世, 斉藤 心, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本胃癌学会総会記事 90回 421-421 2018年3月  
  • Rihito Kanamaru, Hideyuki Ohzawa, Hideyo Miyato, Shiro Matsumoto, Hidenori Haruta, Kentaro Kurashina, Shin Saito, Yoshinori Hosoya, Hironori Yamaguchi, Hiroharu Yamashita, Yasuyuki Seto, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
    Scientific reports 8(1) 632-632 2018年1月12日  査読有り
    Many types of immune cells appear in peritoneal cavity after abdominal surgery. In patients who underwent laparotomy due to gastric cancer, peritoneal lavages were obtained before and after surgical procedure. Cells were recovered from intermediate layer after Ficoll-Hypaque centrifugation and analyzed for phenotypes and functions, especially focused on low density neutrophils (LDN). The number of CD66b (+) LDN with mature phenotype was markedly elevated in postoperative as compared with preoperative lavages. Short term culture of the purified LDN produced many threadlike structures positive for SYTOX, nucleic acid staining, as well as histone and myeloperoxidase, suggesting the NETs formation. Human gastric cancer cells, MKN45, OCUM-1 and NUGC-4, were selectively attached on the NETs, which was totally abolished by the pretreatment of DNAse I. Intraperitoneal (IP) co-transfer of the LDN with MKN45 in nude mice strongly augments the metastasis formation on peritoneum, which was strongly suppressed by the following IP administration of DNAse I. Many NETs-like structures were detected on the surface of human omental tissue resected by gastrectomy. NETs on peritoneal surface can assist the clustering and growth of free tumor cells disseminated in abdomen. Disruption of the NETs by DNAse might be useful to prevent the peritoneal recurrence after abdominal surgery.
  • Shiro Matsumoto, Yoshinori Hosoya, Alan Kawarai Lefor, Hidenori Haruta, Takashi Ui, Kentaro Kurashina, Shin Saito, Kentaro Ashizawa, Takahiro Sasaki, Joji Kitayama, Naohiro Sata
    International journal of surgery case reports 44 118-121 2018年  査読有り
    INTRODUCTION: Black adrenal adenoma (BAA) is a rare, benign adrenal lesion with a black or brown appearance. This is the first report of this lesion in a patient with a synchronous esophageal cancer and highlights the importance of considering a false positive finding on a Positron Emission Tomography (PET) scan, which might otherwise preclude resection. PRESENTATION OF CASE: A 73-year-old male was diagnosed with mid-esophagus carcinoma. Computed tomography scan revealed an enlarged left adrenal gland. Plasma adrenocorticotropic hormones levels were normal. To characterize the adrenal lesion, a PET scan was obtained which showed high uptake of 18F-fluoro-2-deoxy-d-glucose (FDG), consistent with a metastasis, suggesting T3N2M1, clinical stage IV esophageal cancer. After two courses of neo-adjuvant therapy, sub-total esophagectomy and left adrenalectomy were performed. The adrenal tumor was soft, and black in color, diagnosed as a BAA on histology. The pathologic stage of the esophageal cancer was T3N0M0, Stage II. Six months after surgery, he is alive without recurrence. DISCUSSION: High FDG uptake by an adrenal lesion on PET scan, as in this patient, usually suggests a metastatic lesion. Although rare, patients with esophageal cancer and adrenal metastases have been reported to have long-term survival, so it is important to characterize an adrenal lesion when found. CONCLUSION: Most adrenal lesions with high FDG uptake are malignant, but BAA is also positive on PET scan. Although rare, BAA should be considered in patients with solitary adrenal lesions with high uptake on PET scan, even in the presence of a malignancy.
  • Shin Saito, Chao Yan, Hisashi Fukuda, Yoshinori Hosoya, Shiro Matsumoto, Daisuke Matsubara, Joji Kitayama, Alan Kawarai Lefor, Naohiro Sata
    International journal of surgery case reports 44 207-211 2018年  査読有り筆頭著者
    INTRODUCTION: Gastric leiomyomas are benign mesenchymal tumors, comprising about 2.5% of gastric neoplasms, which can be difficult to differentiate from gastrointestinal stromal tumors which have malignant potential. Granular cell tumors in the abdominal wall are also rare. Since mesenchymal tumors are difficult to diagnose by imaging, further studies are needed to establish the diagnosis. PRESENTATION OF CASE: A 60-year-old asymptomatic woman underwent routine upper endoscopy and was found to have a gastric submucosal lesion. Computed tomography scan also showed an abdominal wall mass. The appearance of both lesions on imaging studies were similar, but it was unclear if the two lesions had the same origin. Endoscopic ultrasound-guided fine needle aspiration biopsy of the gastric lesion was insufficient to establish the diagnosis. Laparoscopic-endoscopic cooperative resection of the gastric lesion and ultrasound-guided core-needle biopsy of the abdominal wall mass enabled pathological diagnosis of both lesions. DISCUSSION: Diagnostic imaging findings of these two lesions were similar. Histologic and immunohistochemical studies are essential to establish a definitive diagnosis. Laparoscopic-endoscopic cooperative surgery may be an effective minimally invasive approach, allowing both pathological diagnosis and complete resection of a gastric submucosal tumor, especially when endoscopic-ultrasound guided fine needle aspiration or biopsy fails to make the diagnosis. CONCLUSION: Laparoscopic-endoscopic cooperative surgery can be an effective minimally invasive approach to resect some lesions. This is first report of the patient with a synchronous gastric leiomyoma and an intramuscular granular cell tumor in the abdominal wall.
  • Yurie Futo, Shin Saito, Hideyo Miyato, Ai Sadatomo, Yuki Kaneko, Yoshihiko Kono, Daisuke Matsubara, Hisanaga Horie, Alan Kawarai Lefor, Naohiro Sata
    International journal of surgery case reports 53 358-361 2018年  査読有り責任著者
    INTRODUCTION: Duodenal gastrointestinal tumors (GISTs) are rare. Duodenal GISTs and pancreatic neuroendocrine tumors (NETs) may appear similar on imaging studies. GISTs arising from the second or third portions of duodenum may be incorrectly diagnosed as pancreatic NETs. PRESENTATION OF CASE: The patient is a 79-year-old man who was referred to our hospital with a history of tarry stools and loss of consciousness. Urgent upper digestive tract endoscopy revealed a bleeding submucosal duodenal lesion, which was controlled using endoscopic clips. Enhanced computed tomography scan showed a hyper-vascular mass 50 mm in diameter, at the pancreatic uncus. The patient underwent a pylorus-preserving pancreaticoduodenectomy. Histologically, the tumor was composed of spindle-shaped cells immunohistochemically positive for c-kit and CD34, and the lesion diagnosed as a duodenal GIST. DISCUSSION: Duodenal GISTs often present with gastrointestinal bleeding, which can necessitate emergency surgery. Surgical resection with regional lymph node dissection is the optimal treatment for pancreatic NETs. In contrast, GISTs are generally treated with a minimal resection and without lymph node dissection. Thus, establishing the diagnosis is important in the management of these tumors. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is effective to establish the diagnosis of these lesions. CONCLUSION: A tumor located in the pancreatic head or mesenteric side of the duodenum cannot always be diagnosed based on imaging, and is ideally diagnosed histologically to guide the extent of resection. While EUS-FNA can establish the diagnosis, the complications of this procedure must be considered.
  • 下平 健太郎, 斎藤 心, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会雑誌 50(Suppl.2) 194-194 2017年10月  
  • Shin Saito, Misuzu Nakamura, Yoshinori Hosoya, Joji Kitayama, Alan Kawarai Lefor, Naohiro Sata
    Annals of medicine and surgery (2012) 22 34-38 2017年10月  査読有り筆頭著者
    BACKGROUND: Patients with esophageal cancer and a history of gastrectomy or concurrent gastric cancer undergo not only esophagectomy but also total gastrectomy. The goal of this study is to evaluate the postoperative quality of life (QOL) and dysfunction of these patients using two postoperative questionnaires. MATERIALS AND METHODS: From 1999 to 2015, 41 patients underwent concurrent esophagectomy and total gastrectomy. A jejunal pedicle with the subcutaneous supercharge technique was used for reconstruction. Patients were divided into two groups, including those undergoing concurrent esophagostomy and gastrectomy (Group 1), and those undergoing esophagectomy alone (Group 2, history of previous gastrectomy). Patients were analyzed by time interval, including patients within three years of surgery (Group A) and those more than three years after surgery (Group B). RESULTS: Eighteen patients completed the questionnaires. The mean DAUGS20 score was 26.4 ± 13.2. The DAUGS20 scores of groups 1 (N = 7) and 2 (N = 11) were 25.4 ± 12.5 and 27 ± 15.4 (p = 0.58), respectively. Global health status scored by the EORTC QLQC-30 were 71.4 ± 18.5 in group 1 and 67.4 ± 22.8 in group 2 (p = 0.85). DAUGS20 scores of group A (N = 10) and B (N = 8) were 28.1 ± 12.4 and 23.3 ± 14.4 (p = 0.35). No significant differences were found between groups A and B regarding the QLQ-C30 scores. CONCLUSION: DAUGS20 and QLQ-C30 scores showed no significant differences between groups 1 and 2 or groups A and B. These results suggest that postoperative QOL and dysfunction may be influenced more by current status than by surgical history and postoperative interval. Previous reports describe a DAUGS 20 score after gastrectomy of 27.8 and after esophagectomy of 36.1. The DAUGS20 score of these 18 patients is lower than DAUGS20 scores for patients undergoing either operation alone. Reconstruction using a subcutaneously placed jejunal segment seems to be reasonable.
  • 細谷 好則, 春田 英律, 田口 昌延, 斉藤 心, 倉科 憲太郎, 松本 志郎, 岡田 健太, 海老原 健, 石橋 俊, 矢田 俊彦, 北山 丈二, 佐田 尚宏
    肥満研究 23(Suppl.) 206-206 2017年9月  
  • 金丸 理人, 津久井 秀則, 斉藤 心, 倉科 憲太郎, 松本 志郎, 山口 博紀, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 72回 RS1-2 2017年7月  
  • Shin Saito, Fernando Espinoza-Mercado, Hui Liu, Naohiro Sata, Xiaojiang Cui, Harmik J Soukiasian
    Cancer biology & therapy 18(6) 359-368 2017年6月3日  査読有り筆頭著者
    Lung cancer is the leading cause of cancer-related deaths worldwide with over 1 million deaths each year. The overall prognosis of lung cancer patients remains unsatisfactory, with a 5-year overall survival rate of less than 15%. Although most lung cancers are a result of smoking, approximately 25% of lung cancer cases worldwide are not attributable to tobacco use. Notably, more than half of the lung cancer cases in women occur in non-smokers. Among non-small-cell lung cancer (NSCLC) cases, cigarette-smokers have a greater association with squamous cell carcinoma than adenocarcinoma, which is more common in non-smokers. These findings imply that specific molecular and pathological features may associate with lung adenocarcinoma arising in non-smoker female patients. Over the past decade, whole genome sequencing and other '-omics' technologies led to the discovery of pathogenic mutations that drive tumor cell formation. These technological developments may enable tailored patient treatments throughout the course of their disease, potentially leading to improved patient outcomes. Some clinical and laboratory studies have shown success outcomes using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) in patients with EGFR mutations and ALK rearrangements, respectively. In fact, these 2 mutations are predominantly present in female non-smokers with adenocarcinoma. Immunotherapy has also recently emerged as a major therapeutic modality in NSCLC. In this review, we summarize the current understanding of NSCLC biology and new therapeutic molecular targets, focusing on the pathogenesis of non-smoker female NSCLC patients.
  • 高橋 大二郎, 斎藤 心, 宇井 崇, 倉科 憲太郎, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 71回 P5-4 2017年6月  
  • Shin Saito, Takao Nagashima, Daisuke Matsubara, Noriyoshi Fukushima, Masahiro Iwamoto, Seiji Minota, Hisanaga Horie, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata
    International Surgery 102(5-6) 210-215 2017年5月1日  査読有り筆頭著者
    Eosinophilic granulomatosis with polyangiitis (EGPA) is a vascular disorder of unknown etiology characterized by severe asthma, eosinophilia, and granulomatous vasculitis. It is sometimes associated with gastrointestinal lesions, although perforations are uncommon. Corticosteroids are commonly used in the treatment of patients with EGPA; however, they may impair tissue repair and induce fibrotic changes in the vascular intima, which can lead to vascular occlusion, ischemia, and perforation. The anti-inflammatory properties of corticosteroids may mask symptoms of gastroduodenal ulcers or other intra-abdominal conditions, which can lead to a delay in diagnosis. From January 1, 2001 to December 31, 2014, 71 patients underwent surgery for small intestinal perforations. Of these, 4 operations were performed on 3 patients with EGPA who were receiving corticosteroids. We retrospectively reviewed the clinical and pathologic features of these patients. All 3 patients with EGPA were men, with a mean age of 56 years. The length of resected intestine ranged from 10 to 60 cm. Histopathologic examination revealed ulcers and perforations of the small intestine associated with vasculitis, compatible with EGPA. All patients had an uneventful postoperative course. Patients with EGPA presenting with abdominal pain must be carefully evaluated for possible intestinal perforation, especially those receiving corticosteroid therapy.
  • 北山 丈二, 石神 浩徳, 山口 博紀, 金丸 理人, 松本 志郎, 倉科 憲太郎, 斎藤 心, 細谷 好則, 佐田 尚宏
    日本外科学会定期学術集会抄録集 117回 PD-6 2017年4月  
  • 金丸 理人, 津久井 秀則, 斉藤 心, 倉科 憲太郎, 宇井 崇, 春田 英律, 松本 志郎, 安部 望, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本外科学会定期学術集会抄録集 117回 SF-1 2017年4月  
  • Shin Saito, Yoshinori Hosoya, Misuzu Nakamura, Takashi Ui, Kentaro Kurashina, Shiro Matsumoto, Rihito Kanamru, Joji Kitayama, Alan Lefor, Naohiro Sata
    ANNALS OF BEHAVIORAL MEDICINE 51 S1877-S1878 2017年3月  
  • 北山 丈二, 金丸 理人, 津久井 秀則, 松本 志郎, 倉科 憲太郎, 斎藤 心, 細谷 好則, 山口 博紀, 石神 浩徳, 佐田 尚宏
    日本胃癌学会総会記事 89回 264-264 2017年3月  
  • Shin Saito, Yoshinori Hosoya, Hirofumi Fujii, Hideyuki Ohzawa, Akira Tanaka, Joji Kitayama, Alan Kawarai Lefor, Naohiro Sata
    International Surgery 102(3-4) 137-140 2017年3月1日  査読有り筆頭著者責任著者
    Gastric cancer is a common malignancy and remains potentially lethal. The prognosis of patients with stage IV gastric cancer is thought to be poor, but new molecular targeted therapy may benefit patients with advanced gastric cancer. Currently, conversion surgery after chemotherapy with a trastuzumab-containing regimen is reported to be effective in these patients. We present 3 patients with human epidermal growth factor receptor 2 (HER2)–positive advanced gastric cancer who underwent conversion surgery after receiving a trastuzumab-containing chemotherapy regimen. Interestingly, the primary lesion acquired resistance to the trastuzumab-containing regimen, although the metastatic lesions maintained a complete response. The reason why the primary lesions became resistant to trastuzumab remains unclear. More studies are needed to clarify the mechanism of resistance. Conversion surgery, made possible by the use of molecular-targeted therapy, may improve the prognosis of patients with stage IV gastric cancer, particularly if metastatic lesions show a complete response to therapy.
  • 齋藤 心, 宇井 崇, 倉科 憲太郎, 金丸 理人, 松本 志郎, 堀江 久永, 佐久間 康成, 細谷 好則, 北山 丈二, 佐田 尚宏, 永井 秀雄, 福嶋 敬宜
    日本消化器外科学会雑誌 49(Suppl.2) 126-126 2016年11月  
  • 平瀬 雄規, 齋藤 心, 津久井 秀則, 松本 志郎, 倉科 健太郎, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏
    日本臨床外科学会雑誌 77(11) 2867-2867 2016年11月  
  • 細谷 好則, 斉藤 心, 倉科 憲太郎, 去川 俊二, 中村 美鈴, 佐久間 康成, 堀江 久永, アラン・レフォー, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 71回 PD1-4 2016年7月  
  • 金丸 理人, 斎藤 心, 宇井 崇, 倉科 憲太郎, 細谷 好則, 北山 丈二, 佐田 尚宏, 天野 雄介, 仁木 利郎
    日本食道学会学術集会プログラム・抄録集 70回 137-137 2016年7月  
  • Shin Saito, Kentaro Kurashina, Shiro Matsumoto, Yasunaru Sakuma, Seiji Minota, Masahiro Iwamoto, Daisuke Matsubara, Noriyoshi Fukushima, Hisanaga Horie, Yoshinori Hosoya, Alan K. Lefor, Naohiro Sata
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 137(2) AB165-AB165 2016年2月  査読有り
  • Shin Saito, Yoshinori Hosoya, Kentaro Kurashina, Shiro Matsumoto, Rihito Kanamaru, Takashi Ui, Hidenori Haruta, Joji Kitayama, Alan K Lefor, Naohiro Sata
    International journal of surgery case reports 19 51-4 2016年  査読有り筆頭著者
    INTRODUCTION: Spontaneous esophageal perforation, or Boerhaave's syndrome, is a life-threating condition which usually requires emergent surgery. An upside down stomach is defined as a gastric volvulus in a huge supradiaphragmatic sac. In general, this condition can result in ischemia and perforation of the stomach. This is the first report of a patient with Boerhaave's syndrome and an upside down stomach. CASE PRESENTATION: A 79-year-old woman presented with sudden epigastric pain following hematemesis. Evaluation of the patient showed both an esophageal perforation and an upside down stomach. Surgical drainage and irrigation of the mediastinum and pleural cavities were undertaken emergently. Due to the concurrent gastric volvulus, a gastrostomy was placed to fix and decompress the stomach. The patient had an uneventful hospital course and was discharged. DISCUSSION AND CONCLUSION: Boerhaave's syndrome is a rare but severe complication caused by excessive vomiting, due to a sudden elevation in intraluminal esophageal pressure resulting in esophageal perforation. Acute gastric volvulus can result in ischemia and perforation of the stomach, but has not previously been reported with esophageal perforation. The most likely mechanism associating an upside down stomach with Boerhaave's syndrome is acute gastric outlet obstruction resulting in vomiting, and subsequent esophageal perforation. Perforation of the esophagus as well as perforation of the stomach must be considered in patients with an upside down stomach although both upside down stomach and Boerhaave's syndrome are rare clinical entities.
  • 細谷 好則, 春田 英律, 斉藤 心, 倉科 憲太郎, 宇井 崇, 松本 志郎, 安部 望, 佐久間 康成, 堀江 久永, アラン・レフォー, 佐田 尚宏
    日本内視鏡外科学会雑誌 20(7) OS39-5 2015年12月  
  • 春田 英律, 細谷 好則, 石橋 俊, 斎藤 心, 倉科 憲太郎, 宇井 崇, 松本 志郎, 安部 望, 金丸 理人, 佐田 尚宏
    日本肥満症治療学会学術集会プログラム・抄録集 33回 108-108 2015年6月  
  • Shin Saito, Kazue Morishima, Takashi Ui, Hiroko Hoshino, Daisuke Matsubara, Shumpei Ishikawa, Hiroyuki Aburatani, Masashi Fukayama, Yoshinori Hosoya, Naohiro Sata, Alan K Lefor, Yoshikazu Yasuda, Toshiro Niki
    BMC cancer 15 82-82 2015年2月25日  査読有り筆頭著者
    BACKGROUND: Although advanced esophageal squamous-cell carcinoma (ESCC) is treated using a multidisciplinary approach, outcomes remain unsatisfactory. The microenvironment of cancer cells has recently been shown to strongly influence the biologic properties of malignancies. We explored the effect of supernatant from esophageal fibroblasts on the cell growth and chemo-resistance of ESCC cell lines. METHODS: We used 22 ESCC cell lines, isolated primary human esophageal fibroblasts and immortalized fibroblasts. We first examined cell proliferation induced by fibroblast supernatant. The effect of supernatant was evaluated to determine whether paracrine signaling induced by fibroblasts can influence the proliferation of cancer cells. Next, we examined the effects of adding growth factors HGF, FGF1, FGF7, and FGF10, to the culture medium of cancer cells. These growth factors are assumed to be present in the culture supernatants of fibroblasts and may exert a paracrine effect on the proliferation of cancer cells. We also examined the intrinsic role of HGF/MET and FGFs/FGFR in ESCC proliferation. In addition, we examined the inhibitory effect of lapatinib on ESCC cell lines and studied whether the fibroblast supernatants affect the inhibitory effect of lapatinib on ESCC cell proliferation. Finally, we tested whether the FGFR inhibitor PD-173074 could eliminate the rescue effect against lapatinib that was induced by fibroblast supernatants. RESULTS: The addition of fibroblast supernatant induces cell proliferation in the majority of cell lines tested. The results of experiments to evaluate the effects of adding growth factors and kinase inhibitors suggests that the stimulating effect of fibroblasts was attributable in part to HGF/MET or FGF/FGFR. The results also indicate diversity in the degree of dependence on HGF/MET and FGF/FGFR among the cell lines. Though lapanitib at 1 μM inhibits cell proliferation by more than 50% in the majority of the ESCC cell lines, fibroblast supernatant can rescue the growth inhibition of ESCC cells. However, the rescue effect is abrogated by co-treatment with FGFR inhibitor. CONCLUSION: These results demonstrate that cell growth of ESCC depends on diverse receptor tyrosine kinase signaling, in both cell-autonomous and cell-non-autonomous manners. The combined inhibition of these signals may hold promise for the treatment of ESCC.
  • T. Ui, H. Fujii, Y. Hosoya, M. Nagase, M. N. Mieno, M. Mori, T. Zuiki, S. Saito, K. Kurashina, H. Haruta, S. Matsumoto, T. Niki, A. Lefor, Y. Yasuda
    DISEASES OF THE ESOPHAGUS 28(2) 180-187 2015年2月  査読有り
    We retrospectively compared preoperative docetaxel, cisplatin, and fluorouracil (DCF) with cisplatin and fluorouracil (CF) in patients with esophageal cancer. The study included patients with advanced thoracic esophageal carcinoma (excluding T4 tumors) receiving preoperative chemotherapy. In the DCF group, five patients received two courses of treatment every 4 weeks, and 33 patients received three courses every 3 weeks. In the CF group, 38 patients received two courses of treatment every 4 weeks. Patients underwent curative surgery 4-5 weeks after completing chemotherapy. Patient demographic characteristics did not differ between the two study groups. The incidence of a grade 3 or 4 hematologic toxicity was significantly higher in the DCF group (33 patients) than in the CF group (five patients; P < 0.001). Curative resection was accomplished in 79% of patients in the DCF group and 66% in the CF group (P = 0.305). There were no in-hospital deaths. The incidence of perioperative complications did not differ between the groups. A grade 2 or 3 histological response was attained in a significantly higher proportion of patients in the DCF group (63%) than in the CF group (5%; P < 0.001). Progression-free survival and overall survival were significantly higher in the DCF group (P = 0.013, hazard ratio 0.473; P = 0.001, hazard ratio 0.344). In conclusion, a grade 3 or 4 hematologic toxicity was common in the DCF group but was managed by supportive therapy. Histological response rate, progression-free survival, and overall survival were significantly higher in the DCF group compared with the CF group.
  • Takashi Ui, Kazue Morishima, Shin Saito, Yuji Sakuma, Hirofumi Fujii, Yoshinori Hosoya, Yoshikazu Yasuda, Toshiro Niki
    CANCER RESEARCH 74(19) 2014年10月  
  • 金丸 理人, 細谷 好則, 小松原 利英, 森 和亮, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 斉藤 心, 瑞木 亨, 佐久間 康成, 佐田 尚宏, 安田 是和
    日本臨床外科学会雑誌 75(10) 2940-2940 2014年10月  
  • 細谷 好則, 瑞木 亨, 斉藤 心, 倉科 憲太郎, 春田 英律, 松本 志郎, 安部 望, 宇井 崇, 佐田 尚宏, 安田 是和
    日本内視鏡外科学会雑誌 19(7) 832-832 2014年10月  
  • 春田 英律, 細谷 好則, 石橋 俊, 瑞木 亨, 斎藤 心, 倉科 憲太郎, 松本 志郎, 安部 望, 金丸 理人, 佐田 尚宏, 安田 是和
    日本肥満症治療学会学術集会プログラム・抄録集 32回 85-85 2014年7月  
  • 春田 英律, 細谷 好則, 金丸 理人, 安部 望, 松本 志郎, 倉科 憲太郎, 瑞木 亨, 斎藤 心, 佐田 尚宏, 安田 是和
    日本食道学会学術集会プログラム・抄録集 68回 95-95 2014年7月  
  • Shin Saito, Kazue Morishima, Takashi Ui, Daisuke Matsubara, Tomoko Tamura, Sachiko Oguni, Yoshinori Hosoya, Naohiro Sata, Alan T Lefor, Yoshikazu Yasuda, Toshiro Niki
    Oncology reports 32(1) 348-54 2014年7月  査読有り筆頭著者
    The growth, invasiveness and metastasis of human cancers are determined not only by cancer cells, but also by their microenvironment. Activated stromal fibroblasts promote tumor progression by secreting growth factors. In the present study, we focused on interrelations between cancer and fibroblasts, the main component of tumor stroma. We retrospectively analyzed the relations of mortality to clinical, pathological, and α-smooth muscle actin (α-SMA) characteristics in 97 consecutive patients with esophageal squamous cell carcinoma (ESCC). In vitro, we used TE-11, KYSE150 and KYSE220 ESCC cell lines and isolated esophageal stromal fibroblasts, some of which were immortalized. Migration assays were conducted to assess the effects of fibroblasts on cancer-cell migration and 3-dimensional organotypic cultures. In vivo, TE-11 and KYSE220 cells plus immortalized fibroblasts were co-transplanted subcutaneously in Nod/Scid mice to assess the effects of fibroblasts on tumorigenicity. Clinicopathologically, the α-SMA expression of cancer stroma was correlated with venous invasion (p<0.01), nodal involvement (p=0.02), recurrence (p=0.01), and was a predictor of survival in patients with stage I and II ESCC (p=0.04). In vitro, the presence of fibroblasts strongly promoted the migration of TE-11, KYSE150 and KYSE220 cells. On organotypic culture, stromal invasion was observed only in the presence of immortalized fibroblasts. In vivo, tumors developed or grew in a fibroblast‑dependent manner after implantation. Our findings provide evidence that stromal fibroblasts and tumor cells interact to promote tumor progression in ESCC. In patients with earlier stage ESCC, α-SMA may be a predictor of mortality. Inhibition of paracrine systems associated with tumor fibroblasts may slow or reverse tumor progression, potentially leading to the development of new targeted therapies.
  • Takashi Ui, Kazue Morishima, Shin Saito, Yuji Sakuma, Hirofumi Fujii, Yoshinori Hosoya, Shumpei Ishikawa, Hiroyuki Aburatani, Masashi Fukayama, Toshiro Niki, Yoshikazu Yasuda
    Oncology reports 31(2) 619-24 2014年2月  査読有り
    Although cisplatin (CDDP) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC), acquired chemoresistance remains a major problem. Combination therapy may represent one strategy to overcome this resistance. Heat shock protein 90 (HSP90) is known to be overexpressed in several types of cancer cells, and its inhibition by small molecules, either alone or in combination, has shown promise in the treatment of solid malignancies. In the present study, we evaluated the synergistic effects of combining CDDP with the HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) on two CDDP-resistant human esophageal squamous cancer cell lines, KYSE30 and KYSE150. The results obtained demonstrated the synergistic inhibitory effects of CDDP and 17-AAG on the growth of KYSE30 and KYSE150 cells. Cell growth and cell number were more effectively reduced by the combined treatment with CDDP and 17-AAG than by the treatment with either CDDP or 17-AAG alone. Western blotting revealed that the combined action of CDDP and 17-AAG cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3, which demonstrated that the reduction in both cell growth and cell number was mediated by apoptosis. Time-course experiments showed that reduction in X-linked inhibitor of apoptosis protein (XIAP) and phosphorylated Akt were concomitant with apoptosis. The results of the present study demonstrate that 17-AAG synergizes with CDDP and induces apoptosis in CDDP-resistant ESCC cell lines, and also that modulation of the Akt/XIAP pathway may underlie this synergistic effect. Combination therapy with CDDP and an HSP90 inhibitor may represent a promising strategy to overcome CDDP resistance in ESCC.
  • Toru Zuiki, Yoshinori Hosoya, Yuji Kaneda, Kentaro Kurashina, Shin Saito, Takashi Ui, Hidenori Haruta, Masanobu Hyodo, Naohiro Sata, Alan T Lefor, Yoshikazu Yasuda
    Surgical endoscopy 27(10) 3683-9 2013年10月  査読有り
    BACKGROUND: The double-stapling technique (DST) for esophagojejunostomy using the transorally inserted anvil (OrVil; Covidien Japan, Tokyo, Japan) is one of the reconstruction methods used after laparoscopy-assisted total gastrectomy (LATG). This technique has potential advantages in terms of less invasive surgery without the need to create a complicated intraabdominal anastomosis. METHODS: From 2008 to 2011, 262 patients with gastric cancer underwent total gastrectomy and reconstruction with a Roux-en-Y anastomosis, and 52 patients underwent LATG with DST. A retrospective analysis then was performed comparing the patients who experienced postoperative stenosis after LATG-DST (positive group) and the patients who did not (negative group). A comparative analysis was performed among patients comparing conventional open total gastrectomy and LATG, and multivariate analysis was performed to evaluate risk factors for the development of anastomotic stenosis. RESULTS: A minor leak was found in 1 patient (1.9 %), and 11 patients experienced anastomotic stenosis (21 %) after LATG with DST. Among the patients with anastomotic stenosis, three (3/4, 75 %) anastomoses were performed with the 21-mm end-to-end anastomosis (EEA) stapler, and eight anastomoses were performed (8/47, 17 %) with the 25-mm EEA stapler. The median interval to the diagnosis of anastomotic stenosis was 43 days after surgery. The patients with stenosis needed endoscopic balloon dilation an average of four times, and the rate of perforation after dilation was 13 %. The clinical and operative characteristics did not differ between the two groups. Anastomotic stenosis after open total gastrectomy occurred in two cases (0.98 %). Multivariate analysis showed that the size of the EEA stapler and the use of DST were risk factors for anastomotic stenosis. CONCLUSION: Esophagojejunostomy using DST with OrVil is useful in performing a minimally invasive procedure but carries a high risk of anastomotic stenosis.
  • 春田 英律, 細谷 好則, 倉科 憲太郎, 宇井 崇, 斎藤 心, 瑞木 亨, 中野 今治, 佐田 尚宏, 安田 是和
    外科と代謝・栄養 47(4) 99-104 2013年8月  
    胃切除術後6年目に発症したビタミンB1欠乏による脚気ニューロパチー、衝心脚気の1例を経験したので報告する。患者は58歳男性。胃癌に対して噴門側胃切除術、近位側空腸嚢間置法による再建術を受けた。術後極端な偏食はなく、通常量の食事を摂取していたが、術後の腹部CT検査や内視鏡検査では、毎回間置空腸嚢内に食物残渣が多量に貯留していた。術後6年目に四肢遠位筋優位の筋力低下、異常知覚、両下腿浮腫、易疲労感が出現した。症状は進行し、乳酸アシドーシスと急性心不全を発症した。血中ビタミンB1値は10(正常値20-50)ng/mlと低値であり、ビタミンB1の静脈内投与により症状は劇的に改善した。胃切除術後長期経過症例であっても、近位側空腸嚢間置法による再建術を受け、間置空腸嚢内に残渣が貯留している症例では、潜在的にビタミンB1吸収障害を来しやすい可能性があり、脚気を含めた栄養吸収障害発症のリスクを考慮する必要がある。(著者抄録)
  • 細谷 好則, 西野 宏, 瑞木 亨, 斉藤 心, 宇井 崇, 松本 史郎, 布宮 伸, 倉科 憲太郎, 佐田 尚弘, 安田 是和
    日本消化器外科学会総会 68回 WS-7 2013年7月  
  • 春田 英律, 細谷 好則, 石橋 俊, 多賀谷 信美, 瑞木 亨, 斎藤 心, 倉科 憲太郎, 松本 志郎, 佐田 尚宏, 安田 是和
    日本肥満症治療学会学術集会プログラム・抄録集 31回 89-89 2013年6月  
  • Otohiro Katsube, Shin Saito, Yoshinori Hosoya, Toshihide Komatsubara, Takashi Ui, Kentaro Kurashina, Hidenori Haruta, Toru Zuiki, Takehiko Yamaguchi, Naohiro Sata, Yoshikazu Yasuda
    Clinical journal of gastroenterology 6(3) 207-10 2013年6月  査読有り責任著者
    We report on a 53-year-old male with esophageal cancer. He had no evidence of distant metastasis, and received a subtotal esophagectomy. Histopathologically, the tumors were contiguous with Barrett's epithelium. Undifferentiated carcinoma components existed independently of differentiated adenocarcinoma components. Undifferentiated carcinoma was present proximal to the esophagogastric junction. Both tumors had invaded the submucosa and were associated with a prominent lymphoid stroma. Metastasis from undifferentiated carcinoma was found in the paraesophageal lymph nodes. Immunohistochemically, both components were negative for 34bE12 and positive for CAM5.2 and showed nearly identical staining patterns for p53, indicating that the tumors were derived from Barrett's epithelium. Because the undifferentiated carcinoma did not express CK20 or carcinoembryonic antigen, the properties of adenocarcinoma had apparently been lost during the process of tumor cell progression. This is the first report of undifferentiated carcinoma associated with Barrett's esophagus with adenocarcinoma.
  • 宇井 崇, 細谷 好則, 藤井 博文, 瑞木 亨, 倉科 憲太郎, 斎藤 心, 春田 英律, 松本 志郎, 安田 是和
    日本外科学会雑誌 114(臨増2) 114-114 2013年3月  
  • Shin Saito, Yoshinori Hosoya, Kazue Morishima, Takashi Ui, Hidenori Haruta, Kentaro Kurashina, Yoshiyuki Meguro, Toru Zuiki, Naohiro Sata, Hirofumi Fujii, Daisuke Matsubara, Toshiro Niki, Alan T Lefor, Yoshikazu Yasuda
    Journal of digestive diseases 13(8) 407-13 2012年8月  査読有り筆頭著者
    OBJECTIVE: Adenosquamous carcinoma originating in the stomach is an unusual neoplasm with few existing histological studies. This study was aimed to gain insight into the histogenetic and clinicopathological characteristics of gastric cancer with squamous cell carcinoma (SCC) components. METHODS: From January 2001 to June 2010 a total of 1735 patients underwent a resection of gastric cancer. Histopathologically, eight patients had adenocarcinoma containing SCC components, in which the proportion of SCC components was above 25% of the total tumor mass in four patients. The immunohistochemical and clinicopathological characteristics of these eight patients were analyzed. RESULTS: The median survival duration was 22 months. Adenocarcinoma was present at the superficial layer of all tumors and SCC was primarily present at sites with deep invasion. Immunohistochemically, adenocarcinoma components were positive for cytokeratin (CK) 8/18/19 and CK7 in all cases. SCC components were positive for carcinoembryonic antigen and CK7 in more than 60% of patients. Expression patterns of p53 product were identical in both components. SCC components were positive for 34βE12 and adenocarcinoma components were negative for 34βE12 in all patients. CONCLUSIONS: SCC components are derived from squamous metaplasia in a pre-existing adenocarcinoma. A gastric adenocarcinoma with SCC components is associated with various patterns of metastasis and both SCC and adenocarcinoma components have the potential for metastasis. Gastric cancer with SCC components is a clinically aggressive tumor.
  • 宇井 崇, 細谷 好則, 長瀬 通隆, 藤井 博文, 瑞木 亨, 倉科 憲太郎, 春田 英律, 斎藤 心, 松本 志郎, 安田 是和
    日本消化器外科学会総会 67回 1-1 2012年7月  
  • 俵藤 正信, 細谷 好則, 宇井 崇, 春田 英律, 倉科 憲太郎, 斎藤 心, 瑞木 亨, 安田 是和
    日本食道学会学術集会プログラム・抄録集 66回 241-241 2012年6月  
  • 目黒 由行, 瑞木 亨, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 斉藤 心, 平島 勇希, 細谷 好則, 安田 是和
    日本食道学会学術集会プログラム・抄録集 66回 280-280 2012年6月  
  • 宇井 崇, 細谷 好則, 藤井 博文, 長瀬 通隆, 瑞木 亨, 倉科 憲太郎, 春田 英律, 斎藤 心, 松本 志郎, 安田 是和
    日本食道学会学術集会プログラム・抄録集 66回 316-316 2012年6月  
  • 宇井 崇, 細谷 好則, 長瀬 道隆, 藤井 博文, 瑞木 亨, 春田 英律, 倉科 憲太郎, 斎藤 心, 松本 志郎, 安田 是和
    日本外科学会雑誌 113(臨増2) 499-499 2012年3月  
  • 瑞木 亨, 細谷 好則, 倉科 憲太郎, 春田 英律, 宇井 崇, 斎藤 心, 佐田 尚宏, 安田 是和
    日本胃癌学会総会記事 84回 170-170 2012年2月  
  • 細谷 好則, 瑞木 亨, 春田 英律, 倉科 憲太郎, 斉藤 心, 佐田 尚宏, 安田 是和
    日本内視鏡外科学会雑誌 16(7) 386-386 2011年12月  
  • 宇井 崇, 細谷 好則, 春田 英律, 瑞木 亨, 斉藤 心, 倉科 憲太郎, 金丸 理人, Lefor Alan, 佐田 尚宏, 安田 是和
    日本内視鏡外科学会雑誌 16(7) 411-411 2011年12月  
  • 瑞木 亨, 細谷 好則, 春田 英律, 宇井 崇, 斎藤 心, 倉科 憲太郎, 段ノ上 秀雄, 中村 美鈴, 佐田 尚宏, 安田 是和
    日本内視鏡外科学会雑誌 16(7) 475-475 2011年12月  

主要なMISC

 155

主要な講演・口頭発表等

 28

共同研究・競争的資金等の研究課題

 4